EP Patent

EP4226926A1 — Stable ready-to-dilute pharmaceutical formulation comprising cyclophosphamide

Assigned to Extrovis AG · Expires 2023-08-16 · 3y expired

What this patent protects

The present invention relates to a stable formulation of cyclophosphamide comprising a therapeutically effective amount of cyclophosphamide, ethanol as solvent, polyethylene glycol as the solvent, and optionally, monothioglycerol as the anti-oxidant, wherein the composition is st…

USPTO Abstract

The present invention relates to a stable formulation of cyclophosphamide comprising a therapeutically effective amount of cyclophosphamide, ethanol as solvent, polyethylene glycol as the solvent, and optionally, monothioglycerol as the anti-oxidant, wherein the composition is stable over its shelf life.

Drugs covered by this patent

Patent Metadata

Patent number
EP4226926A1
Jurisdiction
EP
Classification
—
Expires
2023-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Extrovis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.